Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. (MRSN) Revenue
Annual & quarterly revenue history · segment & region breakdown
MRSN · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsMersana Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.03B, an increase of 9.88% year-over-year from $0.04B in FY2024.
Revenue trend
2024 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.04B | +$0.00B | +9.88% |
| 2023-12-31 | $0.04B | +$0.01B | +38.65% |
| 2022-12-31 | $0.03B | +$0.03B | +61716.28% |
| 2021-12-31 | $0.00B | -$0.00B | -94.81% |
| 2020-12-31 | $0.00B | -$0.04B | -98.03% |
| 2019-12-31 | $0.04B | +$0.03B | +297.61% |
| 2018-12-31 | $0.01B | -$0.01B | -39.62% |
| 2017-12-31 | $0.02B | -$0.01B | -30.30% |
| 2016-12-31 | $0.03B | +$0.01B | +142.99% |
| 2015-12-31 | $0.01B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Mersana Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Mersana Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Mersana Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MRSN revenue · 4 questionsMRSN's trailing twelve-month (TTM) revenue is $0.03B. That is an increase of 9.88% year-over-year from $0.04B in FY2024.
▸ Source: FMP · Mersana Therapeutics, Inc. SEC filings · GAAP · Mersana Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026